维利西呱与心力衰竭反向重构指标 (VERI-PATH)
维利西呱对心脏逆重构指标的影响:射血分数降低型心力衰竭治疗的病理生理学方法
The goal of this clinical trial is to investigate how vericiguat benefits adults with stable heart failure with reduced ejection fraction (HFrEF) who are already receiving guideline-directed medical therapy.
The main questions are:
- Does vericiguat improve right ventricular systolic function, measured by fractional area change (FAC)?
- Does vericiguat favourably influence myocardial remodeling, fibrosis, angiogenesis, inflammation, metabolism, renal function, and hematologic balance?
- Do genetic and oxidative stress profiles modify treatment response? Researchers will compare a group receiving vericiguat plus usual care with a group receiving usual care alone to assess structural, functional, and biomarker changes over 12 months.
Participants will:
- Have blood drawn at baseline and follow-up visits for biomarker, metabolomic, genetic, transcriptomic, and hematologic analyses, including platelet function testing
- Perform oral glucose tolerance tests (OGTT) to assess insulin resistance
- Undergo echocardiography, cardiac magnetic resonance imaging, and cardiac scintigraphy to evaluate heart structure, function, and perfusion
- Attend follow-up visits at 1, 3, 6, and 12 months Open-label extension: After the 12-month randomized phase, participants originally assigned to usual care will be offered open-label vericiguat and followed for an additional 12 months. This exploratory extension will reassess study outcomes to evaluate the consistency and magnitude of response to vericiguat in the prior control cohort.
研究概览
地位
详细说明
Heart failure with reduced ejection fraction (HFrEF) involves pathologic processes that lead to maladaptive remodeling of the myocardium with ventricular dilation, wall thickening, and cellular and microvascular changes that progressively worsen cardiac function. Many established therapies for heart failure can promote reverse remodeling, improving symptoms and long-term outcomes.
Vericiguat is a soluble guanylate cyclase (sGC) stimulator that increases cyclic guanosine monophosphate (cGMP), a signaling molecule with vasodilatory and cardioprotective effects that is impaired in heart failure. Randomized trials show that vericiguat reduces the risk of worsening heart-failure events in HFrEF after recent decompensation, and emerging evidence indicates that these benefits extend to stable HFrEF. The mechanisms by which vericiguat may benefit patients with HFrEF remain incompletely understood.
Preclinical data suggest that augmenting cGMP signaling may confer antifibrotic, antihypertrophic, antiinflammatory, proangiogenic, and metabolic effects. These mechanisms could contribute to reverse remodeling and improved clinical status, but they require confirmation in a clinical setting.
This randomized, controlled study will evaluate the effects of vericiguat on right ventricular systolic function, assessed by fractional area change (FAC), and will characterize associated structural and biologic changes in adults with stable HFrEF on contemporary GDMT. Sixty participants will be randomized to vericiguat plus usual care or to usual care alone and followed for 12 months, with study visits at 1, 3, 6, and 12 months.
At each visit, blood samples will be collected for analysis of circulating biomarkers reflecting fibrosis, inflammation, angiogenesis, renal function, and metabolism, as well as transcriptomic profiling. Comprehensive metabolomic profiling will be performed, and insulin resistance will be evaluated by oral glucose tolerance testing (OGTT) at baseline and 12 months. Hematologic parameters will be measured at each visit, while platelet function will be assessed at baseline and 12 months.
Cardiac structure and function will be assessed using transthoracic echocardiography, cardiac magnetic resonance imaging, and cardiac scintigraphy. Imaging will quantify biventricular volumes, systolic function, fibrosis, and perfusion.
The study will investigate whether cumulative oxidative stress and genetic variation modify the response to vericiguat. Cumulative oxidative stress will be quantified from serial 8-hydroxy-2'-deoxyguanosine (8-OHdG) measurements (area under the curve) and examined for interaction with treatment effects on TAPSE and other outcomes. Genetic analyses will assess variants in drug-disposition and NO-sGC-cGMP pathway genes for associations with response.
After completing the 12-month randomized phase, participants originally assigned to usual care will be offered open-label vericiguat and followed for an additional 12 months. This non-randomized, exploratory extension will re-measure the randomized-phase outcomes to evaluate the consistency and magnitude of response to vericiguat in the prior control cohort, using Month 12 values as the extension baseline.
Overall, this research is designed to clarify the pathophysiologic mechanisms of vericiguat therapy in HFrEF and to support more personalized treatment strategies for patients living with heart failure.
研究类型
注册 (估计的)
阶段
- 第四阶段
联系人和位置
学习联系方式
- 姓名:Tine Bajec, MD
- 电话号码:+386 051727249
- 邮箱:tine.bajec@kclj.si
学习地点
-
-
-
Izola、斯洛文尼亚、6310
- 招聘中
- Division of Internal Medicine, Izola General Hospital
-
接触:
- Tinkara Ravnikar, MD
- 电话号码:+386 5 6606 000
- 邮箱:info@sb-izola.si
-
Ljubljana、斯洛文尼亚、1000
- 招聘中
- University Medical Centre Ljubljana
-
接触:
- Tine Bajec, MD
- 电话号码:+386 051727249
- 邮箱:tine.bajec@kclj.si
-
接触:
-
副研究员:
- Tine Bajec, MD
-
首席研究员:
- Gregor Poglajen, MD, PhD
-
副研究员:
- Gregor Zemljič, MD, PhD
-
副研究员:
- Andraž Cerar, MD, PhD
-
副研究员:
- Miran Šebeštjen, MD, PhD
-
副研究员:
- Neža Žorž, MD
-
副研究员:
- Sabina Frljak, MD, PhD
-
副研究员:
- Renata Okrajšek, MD, PhD
-
副研究员:
- Sabina Ugovšek, MD
-
副研究员:
- Petra Girandon Sušanj, MD
-
Ljubljana、斯洛文尼亚、1000
- 招聘中
- Clinical Department of Vascular Diseases, University Medical Centre Ljubljana
-
接触:
- Borut Jug, MD
- 电话号码:+386 (01) 522 80 11
- 邮箱:borut.jug@kclj.si
-
Maribor、斯洛文尼亚、2000
- 招聘中
- University Department of Cardiology and Angiology, University Medical Centre Maribor
-
接触:
- David Šuran, MD
- 电话号码:+386 (0)2 321 28 13
- 邮箱:gpisarna@ukc-mb.si
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Written informed consent from an adult patient (≥ 18 years old) to participate in the clinical study,
- Stable HFrEF defined as no heart failure worsening in the 6 months before randomization that required hospitalization or outpatient diuretic treatment,
- Confirmed diagnosis of chronic heart failure with reduced ejection fraction (LVEF < 50%, confirmed by echocardiography) within 12 months before randomization,
- Stable GDMT for HFrEF for at least 3 months prior to randomisation.
Exclusion Criteria:
- Systolic blood pressure < 100 mmHg or symptomatic hypotension,
- Current or planned use of long-acting nitrates, soluble guanylate cyclase stimulators, or phosphodiesterase type V inhibitors,
- Known allergy/hypersensitivity to soluble guanylate cyclase stimulators,
- Awaiting heart transplantation or dependence on continuous inotropic therapy
- Cardiac amyloidosis, sarcoidosis, myocarditis, stress cardiomyopathy, or tachycardic cardiomyopathy,
- Acute coronary syndrome, coronary artery bypass grafting, or percutaneous coronary intervention in the past three months before randomisation,
- Long-term mechanical circulatory support of the left ventricle,
- Active infection,
- Chronic kidney disease stage 4 or 5, and
- Advanced liver failure classified as Child-Pugh B or C.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Vericiguat + GDMT
Participants will receive vericiguat added to guideline-directed medical therapy (GDMT) for heart failure. Vericiguat will be initiated at 2.5 mg once daily and up-titrated in approximately 2-week intervals to 5 mg and then a target dose of 10 mg once daily, as tolerated, over the 12-month randomized phase. |
Oral soluble guanylate cyclase stimulator administered once daily, initiated at 2.5 mg and up-titrated in approximately 2-week intervals to 5 mg and then 10 mg as tolerated, in addition to guideline-directed medical therapy for heart failure.
其他名称:
Standard combination heart failure therapy according to current guidelines (ARNI, beta-blocker, MRA, and SGLT2 inhibitor as tolerated).
其他名称:
|
|
有源比较器:GDMT
Participants will continue to receive guideline-directed medical therapy (GDMT) for heart failure without vericiguat during the 12-month randomized phase (vericiguat offered during exploratory extension). |
Standard combination heart failure therapy according to current guidelines (ARNI, beta-blocker, MRA, and SGLT2 inhibitor as tolerated).
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in right ventricular systolic function assessed by right ventricular fractional area change (RV FAC)
大体时间:Baseline to 6 months and 12 months
|
Change in RV FAC (%), measured by transthoracic echocardiography (TTE) in the apical four-chamber view. |
Baseline to 6 months and 12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in left ventricular systolic function assessed by left ventricular ejection fraction (LVEF)
大体时间:Baseline to 6 months and 12 months
|
Change in LVEF (%), measured by transthoracic echocardiography using 2D biplane Simpson's method. |
Baseline to 6 months and 12 months
|
|
Change in left ventricular systolic function assessed by left ventricular global longitudinal strain (GLS)
大体时间:Baseline to 6 months and 12 months
|
Change in left ventricular GLS (%), measured by transthoracic echocardiography using speckle-tracking. |
Baseline to 6 months and 12 months
|
|
Change in left ventricular structure assessed by left ventricular mass index (LVMI)
大体时间:Baseline to 6 months and 12 months
|
Change in LVMI (g/m²), calculated from transthoracic echocardiography using the Devereux formula and indexed to body surface area. |
Baseline to 6 months and 12 months
|
|
Change in right ventricular systolic function assessed by tricuspid annular plane systolic excursion (TAPSE)
大体时间:Baseline to 6 months and 12 months
|
Change in TAPSE (mm), measured by transthoracic echocardiography in the apical four-chamber view using M-mode. |
Baseline to 6 months and 12 months
|
|
Change in circulating serum fibrosis biomarkers assessed by Galectin-3 (Gal-3) and soluble ST2 (sST2)
大体时间:Baseline, 1 month, 3 months, 6 months, and 12 months
|
Change in serum Gal-3 (ng/mL) and sST2 (ng/mL) concentrations, measured in peripheral blood samples. |
Baseline, 1 month, 3 months, 6 months, and 12 months
|
|
Change in serum angiogenetic biomarkers assessed by angiogenesis-related biomarker panel composite score
大体时间:Baseline, 1 month, 3 months, 6 months, and 12 months
|
Change in angiogenesis-related biomarker panel composite score, measured using a Luminex multiplex immunoassay (Human XL Cytokine Luminex® Performance Assay 46-plex). |
Baseline, 1 month, 3 months, 6 months, and 12 months
|
|
Change in systemic inflammation assessed by serum inflammatory biomarker panel composite score
大体时间:Baseline, 1 month, 3 months, 6 months, and 12 months
|
Change in serum inflammatory biomarker panel composite score, measured using a Luminex multiplex immunoassay (Human XL Cytokine Luminex® Performance Assay 46-plex). |
Baseline, 1 month, 3 months, 6 months, and 12 months
|
|
Change in cardiac fibrosis assessed by the extent of late gadolinium enhancement (LGE)
大体时间:Baseline to 12 months
|
Change in extent of myocardial LGE (% of left ventricular mass), quantified by cardiac magnetic resonance (CMR). |
Baseline to 12 months
|
|
Change in myocardial microvascular dysfunction assessed by quantitative myocardial perfusion scintigraphy
大体时间:Baseline to 12 months
|
Change in myocardial blood flow (MBF, mL/min/g), measured by quantitative myocardial perfusion scintigraphy. |
Baseline to 12 months
|
|
Change in insulin sensitivity assessed by the Matsuda index
大体时间:Baseline and 12 months
|
Change in insulin sensitivity measured by the Matsuda index (unitless), derived from a standard 75-g oral glucose tolerance test (OGTT). |
Baseline and 12 months
|
|
Change in kidney function assessed by urine albumin-to-creatinine ratio (UACR)
大体时间:Baseline, 1 month, 3 months, 6 months, and 12 months
|
Change in UACR (mg/g), measured from a spot urine sample. |
Baseline, 1 month, 3 months, 6 months, and 12 months
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Difference in right ventricular systolic function assessed by right ventricular fractional area change (RV FAC) between genotype groups
大体时间:Genotyping at baseline; RV FAC change from baseline to 12 months
|
Difference in change in RV FAC (%), measured by transthoracic echocardiography, between patients with wild-type vs mutated UGT1A9 gene, assessed by genotyping/sequencing from peripheral blood samples. |
Genotyping at baseline; RV FAC change from baseline to 12 months
|
|
Change in pre-specified gene set expression score, assessed by peripheral blood RNA-seq
大体时间:Baseline, 1 month, 3 months, 6 months, and 12 months
|
Change in expression score of a pre-specified gene set (unitless normalized RNA-seq expression score), assessed by peripheral blood RNA sequencing (RNA-seq). |
Baseline, 1 month, 3 months, 6 months, and 12 months
|
|
Difference in right ventricular systolic function assessed by right ventricular fractional area change (RV FAC) between high versus low oxidative stress groups
大体时间:Time Frame: 8-OHdG at baseline, 1 month, 3 months, 6 months, and 12 months; RV FAC change from baseline to 12 months
|
Difference in change in RV FAC (%), measured by transthoracic echocardiography, between participants with high versus low oxidative stress defined by the median of the 12-month urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) area-under-the-curve (AUC, ng/mL·month), measured by validated immunoassay. |
Time Frame: 8-OHdG at baseline, 1 month, 3 months, 6 months, and 12 months; RV FAC change from baseline to 12 months
|
合作者和调查者
调查人员
- 首席研究员:Gregor Poglajen, MD, PhD、Advanced Heart Failure and Transplantation Center, Department of Cardiology, University Medical Centre Ljubljana, Ljubljana, Slovenia
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 0120-5/2025-2711-3
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Deidentified individual participant data (IPD) that underlie the results reported in future publications (text, tables, figures, and appendices) will be shared upon reasonable request. Shared IPD will include baseline characteristics, outcome measures, and relevant biomarker data, excluding data that could compromise participant privacy or institutional confidentiality.
IPD 共享时间框架
IPD will be made available within 6 months after publication of the main results and will remain accessible for at least 5 years thereafter.
IPD 共享访问标准
Researchers whose proposed use of the data is approved by the principal investigator will be granted access. Proposals should include a concise research plan and statistical analysis outline. Requests should be submitted to tine.bajec@kclj.si. Approved requesters will sign a data sharing agreement to ensure data confidentiality and appropriate use.
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.